These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 33920965)

  • 1. The Advantages and Challenges of Using Endolysins in a Clinical Setting.
    Murray E; Draper LA; Ross RP; Hill C
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33920965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriophage and peptidoglycan degrading enzymes with antimicrobial applications.
    Donovan DM
    Recent Pat Biotechnol; 2007; 1(2):113-22. PubMed ID: 19075835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endolysins as antimicrobials.
    Nelson DC; Schmelcher M; Rodriguez-Rubio L; Klumpp J; Pritchard DG; Dong S; Donovan DM
    Adv Virus Res; 2012; 83():299-365. PubMed ID: 22748813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage endolysins as a novel class of antibacterial agents.
    Borysowski J; Weber-Dabrowska B; Górski A
    Exp Biol Med (Maywood); 2006 Apr; 231(4):366-77. PubMed ID: 16565432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review of the applications of bacteriophage-derived endolysins for foodborne bacterial pathogens and food safety: recent advances, challenges, and future perspective.
    Khan FM; Chen JH; Zhang R; Liu B
    Front Microbiol; 2023; 14():1259210. PubMed ID: 37869651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriophage endolysins: applications for food safety.
    Schmelcher M; Loessner MJ
    Curr Opin Biotechnol; 2016 Feb; 37():76-87. PubMed ID: 26707470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.
    Oliveira H; São-José C; Azeredo J
    Viruses; 2018 May; 10(6):. PubMed ID: 29844287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibacterial synergy between a phage endolysin and citric acid against the Gram-negative kiwifruit pathogen
    Sisson HM; Fagerlund RD; Jackson SA; Briers Y; Warring SL; Fineran PC
    Appl Environ Microbiol; 2024 Mar; 90(3):e0184623. PubMed ID: 38319087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria.
    Gerstmans H; Rodríguez-Rubio L; Lavigne R; Briers Y
    Biochem Soc Trans; 2016 Feb; 44(1):123-8. PubMed ID: 26862197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria.
    Briers Y; Lavigne R
    Future Microbiol; 2015; 10(3):377-90. PubMed ID: 25812461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Screening, and Characterization of Engineered Phage Endolysins with Extracellular Antibacterial Activity against Gram-Negative Bacteria.
    Sui B; Wang X; Zhao T; Zhen J; Ren H; Liu W; Zhang X; Zhang C
    Appl Environ Microbiol; 2023 Jul; 89(7):e0058123. PubMed ID: 37338346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections.
    Gondil VS; Harjai K; Chhibber S
    Int J Antimicrob Agents; 2020 Feb; 55(2):105844. PubMed ID: 31715257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning and expression analysis of fused holin-endolysin from RL bacteriophage; Exhibits broad activity against multi drug resistant pathogens.
    Basit A; Qadir S; Qureshi S; Rehman SU
    Enzyme Microb Technol; 2021 Sep; 149():109846. PubMed ID: 34311883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens.
    Briers Y; Walmagh M; Van Puyenbroeck V; Cornelissen A; Cenens W; Aertsen A; Oliveira H; Azeredo J; Verween G; Pirnay JP; Miller S; Volckaert G; Lavigne R
    mBio; 2014 Jul; 5(4):e01379-14. PubMed ID: 24987094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection.
    Schmelcher M; Shen Y; Nelson DC; Eugster MR; Eichenseher F; Hanke DC; Loessner MJ; Dong S; Pritchard DG; Lee JC; Becker SC; Foster-Frey J; Donovan DM
    J Antimicrob Chemother; 2015 May; 70(5):1453-65. PubMed ID: 25630640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and biophysical characterization of PlyGRCS, a bacteriophage endolysin active against methicillin-resistant Staphylococcus aureus.
    Linden SB; Zhang H; Heselpoth RD; Shen Y; Schmelcher M; Eichenseher F; Nelson DC
    Appl Microbiol Biotechnol; 2015 Jan; 99(2):741-52. PubMed ID: 25038926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.
    Liu H; Hu Z; Li M; Yang Y; Lu S; Rao X
    J Biomed Sci; 2023 Apr; 30(1):29. PubMed ID: 37101261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DUF3380 Domain from a Salmonella Phage Endolysin Shows Potent N-Acetylmuramidase Activity.
    Rodríguez-Rubio L; Gerstmans H; Thorpe S; Mesnage S; Lavigne R; Briers Y
    Appl Environ Microbiol; 2016 Aug; 82(16):4975-81. PubMed ID: 27287318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structure and function of modular Escherichia coli O157:H7 bacteriophage FTBEc1 endolysin, LysT84: defining a new endolysin catalytic subfamily.
    Love MJ; Coombes D; Ismail S; Billington C; Dobson RCJ
    Biochem J; 2022 Jan; 479(2):207-223. PubMed ID: 34935873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria.
    Khan FM; Rasheed F; Yang Y; Liu B; Zhang R
    Front Pharmacol; 2024; 15():1385261. PubMed ID: 38831886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.